GSK suffers patent blow in India


India's Intellectual Property Appellate Board (IPAB) has voided a GlaxoSmithKline (GSK) patent for the company's Tykerb breast cancer drug, although it has affirmed intellectual property on the treatment's active pharmaceutical ingredient, lapatinib.

IPAB's decision follows a supreme court ruling in April that disallowed patents for incremental innovation.

The verdict is a semi-victory for Fresenius (FMS), which had challenged the patents on the original molecule and its marketed version Tykerb, saying they lacked innovation.

However, the decision is the latest IP blow to Big Pharma in India, where patents granted to Novartis, Pfizer, Roche and Merck have all been invalidated in the last year or so, due to lack of innovation.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs